Intellia Therapeutics (NTLA) Revenue (2016 - 2025)
Historic Revenue for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $13.8 million.
- Intellia Therapeutics' Revenue rose 5126.77% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 3351.9%. This contributed to the annual value of $57.9 million for FY2024, which is 5955.07% up from last year.
- Per Intellia Therapeutics' latest filing, its Revenue stood at $13.8 million for Q3 2025, which was up 5126.77% from $14.2 million recorded in Q2 2025.
- Intellia Therapeutics' Revenue's 5-year high stood at $28.9 million during Q1 2024, with a 5-year trough of -$1.9 million in Q4 2023.
- For the 5-year period, Intellia Therapeutics' Revenue averaged around $11.4 million, with its median value being $12.9 million (2021).
- As far as peak fluctuations go, Intellia Therapeutics' Revenue surged by 432200.0% in 2022, and later plummeted by 11412.36% in 2023.
- Over the past 5 years, Intellia Therapeutics' Revenue (Quarter) stood at $12.9 million in 2021, then grew by 5.59% to $13.6 million in 2022, then tumbled by 114.12% to -$1.9 million in 2023, then skyrocketed by 771.57% to $12.9 million in 2024, then rose by 7.05% to $13.8 million in 2025.
- Its last three reported values are $13.8 million in Q3 2025, $14.2 million for Q2 2025, and $16.6 million during Q1 2025.